I sit down with Dr Asaf Maoz, Medical Oncologist at Dana Farber Cancer Institute, who I recently saw at the LynkedIn and Scientific Symposium. We discussed what brought Dr Maoz to this point, discussing immunology, T-cells, receptors and targets. Dr Maoz confirmed that not all Lynch cancers are MSI-H. This year, for the 5 year anniversary of the patient LynkedIn conference, they had the scientific symposium the day before. Dr Michael Foote from MSK presented some data on cancer risk after immunotherapy. I appreciate the debates and conversations that take place at the symposiums, and how data will continue to drive innovation, but like anything, until you generate the data you can't hypothesize and stratify. Of course we ventured into the cancer vaccine space and the unique molecular features of Lynch Syndrome and the potential to prevent cancer in the future. Takeaway is to keep up with screening regardless. We also discussed language barriers to healthcare overall, not just Lynch Syndrome, including how AI is being looked at in order to potentially find tidbits that are missed.
Information
- Show
- FrequencyTwice monthly
- Published21 April 2024 at 12:25 UTC
- Length46 min
- RatingClean